European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank
chILD-EU
Orphans Unite: chILD Better Together - European Management Platform for Childhood Interstitial Lung Diseases / chILD-EU - International Register and Biobank for Children´s Interstital Lung Disease
1 other identifier
observational
1,000
3 countries
3
Brief Summary
Generation of a common European database and biobank Continous assessment and implementation of guidelines and treatment protocols Establishment of a large observational cohort of chILD patients Determination the value of outcomes used in child Assess treatment variations used, deliver data from defined protocols and linked outcomes
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Dec 2013
Longer than P75 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2013
CompletedFirst Submitted
Initial submission to the registry
July 29, 2016
CompletedFirst Posted
Study publicly available on registry
August 2, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2029
September 21, 2022
September 1, 2022
15 years
July 29, 2016
September 18, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Included subjects with specific diagnosis
Number of recruited subjects
10 years
Secondary Outcomes (1)
Survial
10 years
Eligibility Criteria
400 prevalent patients with childhood interstitial lung disease (chILD) in Europe 100 incident chILD cases per year
You may qualify if:
- all children with suspected or
- verified diagnosis of ILD or
- masquerading as ILD and
- those with rare localized parenchymal lung diseases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Matthias Grieselead
Study Sites (3)
Medizinische Hochschule Hannover
Hanover, Lower Saxony, 30625, Germany
Hacettepe University, Medical Faculty
Ankara, Sihhiye, 06100, Turkey (Türkiye)
University of Edinburgh
Edinburgh, EH4 2XU, United Kingdom
Related Publications (1)
Griese M, Seidl E, Hengst M, Reu S, Rock H, Anthony G, Kiper N, Emiralioglu N, Snijders D, Goldbeck L, Leidl R, Ley-Zaporozhan J, Kruger-Stollfuss I, Kammer B, Wesselak T, Eismann C, Schams A, Neuner D, MacLean M, Nicholson AG, Lauren M, Clement A, Epaud R, de Blic J, Ashworth M, Aurora P, Calder A, Wetzke M, Kappler M, Cunningham S, Schwerk N, Bush A; the other chILD-EU collaborators. International management platform for children's interstitial lung disease (chILD-EU). Thorax. 2018 Mar;73(3):231-239. doi: 10.1136/thoraxjnl-2017-210519. Epub 2017 Oct 22.
PMID: 29056600BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Matthias Griese, Prof.
Klinikum der Universität München, Dr. von Haunersches Kinderspital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Target Duration
- 10 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Prof. Dr. med.
Study Record Dates
First Submitted
July 29, 2016
First Posted
August 2, 2016
Study Start
December 1, 2013
Primary Completion (Estimated)
December 1, 2028
Study Completion (Estimated)
December 1, 2029
Last Updated
September 21, 2022
Record last verified: 2022-09
Data Sharing
- IPD Sharing
- Will not share